The estimated Net Worth of Sankesh Abbhi is at least 588 千$ dollars as of 15 July 2020. Sankesh Abbhi owns over 46,779 units of Brainstorm Cell Therapeutics stock worth over 587,670$ and over the last 4 years he sold BCLI stock worth over 0$. In addition, he makes 0$ as Director at Brainstorm Cell Therapeutics.
Sankesh has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 46,779 units of BCLI stock worth 607,659$ on 15 July 2020.
The largest trade he's ever made was buying 46,779 units of Brainstorm Cell Therapeutics stock on 15 July 2020 worth over 607,659$. On average, Sankesh trades about 15,593 units every 0 days since 2020. As of 15 July 2020 he still owns at least 2,164,530 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Sankesh Abbhi stock trades at the bottom of the page.
Sankesh Abbhi is the Director at Brainstorm Cell Therapeutics.
Sankesh's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over 1,899,994$ worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth 1,535,874$ . The most active insiders traders include Corp. Accbt、Mike Frankenberger、International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of 206,459$. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth 22,050$.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: